SEMORINEMAB
UNII O8DG8VI95O

Substance Identification & Data

This profile provides standardized clinical and technical data for Semorinemab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) O8DG8VI95O.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2159141-27-0 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

O8DG8VI95O

CAS Registry Number

2159141-27-0

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

SEMORINEMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C174790

National Cancer Institute reference terminology for clinical and research data.

INN ID

11024

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

GH-168

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Semorinemab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

SEMORINEMAB

Common Names & Synonyms

SEMORINEMAB [INN]

SEMORINEMAB [USAN]

SEMORINEMAB [WHO-DD]

Systematic Nomenclature

IMMUNOGLOBULIN G4, ANTI-(HUMAN TAU PROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL RO7105705 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RO7105705 .KAPPA.-CHAIN, DIMER

SYS

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS MAPT (MICROTUBULE-ASSOCIATED PROTEIN TAU, TAU)), MONOCLONAL ANTIBODYGAMMA4 HEAVY CHAIN (1-444) (VH (HOMO SAPIENS IGHV3-23*03 (88.7%)-(IGHD)-IGHJ4*01 (100%)) (8.8.10) (1-117)-HOMO SAPIENS IGHG4*01 (CH1 (118-215), HINGE S10>P (225) (216-227), CH2 M15.1>Y (249), S16>T (251), T18>E (253) (228-337), CH3 (338-442), CHS (443-444)) (118-444)), (131-219')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-219') (V-KAPPA (MUS MUSCULUS IGKV1-117*01 (90.0%)-IGKJ4*01(83.3%)/HOMO SAPIENS IGKV2-4*01 (85.4%)-IGKJ1*01 (100%)) (11.3.9) (1'-112')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (158), V101 (196) (113'-219'))DIMER (223-223'':226-226'')-BISDISULFIDE

SYS

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS MICROTUBULE-ASSOCIATED PROTEIN TAU (NEUROFIBRILLARY TANGLE PROTEIN, PAIRED HELICAL FILAMENT-TAU, PHF-TAU))MONOCLONAL ANTIBODY.GAMMA.4 HEAVY CHAIN (1-444) (VH (HOMO SAPIENS IGHV3-23*03 (89%) (IGHD)-IGHJ4*01) (8.8.10) (1-117)-HOMO SAPIENS IGHG4*01 (HINGE(S10>P(225)), CH2(M22>Y(249),S24>T(251),T26>E(253))) (118-444)), (131-219')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-219') (V-KAPPA (MUS MUSCULUS IGKV1-117*01 (90%) IGKJ1*01 (83%) (11.3.10)/HOMO SAPIENS IGKV2-40*01 (85%) IGKJ1*01 (11.3.9)) (1'-112')-HOMO SAPIENS IGKC*01 (113'-219')), DIMER (223-223'':226-226'')-BISDISULFIDE

SYS